CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionDebt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.12×)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.40BUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.36xvs all stocks
52-Week Change
56.66%vs all stocks
Market Capitalization
1.40BUSDvs all stocks (USD)
Enterprise Value
1.03BUSDvs all stocks (USD)
Forward P/E
-7.48xvs Biotechnology peers
Price to Book (MRQ)
3.75xvs Biotechnology peers
Enterprise to EBITDA
-5.80xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-33.11%vs Biotechnology peers
Return on Equity (TTM)
-53.25%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Sep 26, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
0.00USDvs all stocks (USD)
Net Income (TTM)
-164.21MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-147.93MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-89.48MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 26, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-177.53MUSDvs all stocks (USD)
Pre-tax Income
-166.31MUSDFY2025 · Dec 31, 2025Net Income
-166.31MUSDFY2025 · Dec 31, 2025EBIT
-177.53MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-177.53MUSDFY2025 · Dec 31, 2025Research & Development
153.35MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
24.18MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
11.23MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-166.31MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-154.69MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
45.54MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-166.31MUSDFY2025 · Dec 31, 2025Stock-based Compensation
12.52MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-3.03MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
2.14MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-21.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-272.93MUSDFY2025 · Dec 31, 2025Sale of Investments
201.71MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-71.23MUSDFY2025 · Dec 31, 2025Other Financing Charges
-70.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
202.56MUSDFY2025 · Dec 31, 2025Shares Outstanding
48.32MSharesUpdated Sep 26, 2026Float Shares
32.11MSharesUpdated Sep 26, 2026Shares Short
8.77MSharesUpdated Sep 26, 2026Short Ratio
18.89daysvs all stocks
Short % of Shares Outstanding
18.86%vs all stocks
% Held by Insiders
1.54%vs all stocks
% Held by Institutions
98.78%vs all stocks
Total Cash (MRQ)
373.12MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
7.57USDUpdated Sep 26, 2026Total Debt (MRQ)
351.00KUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0010xvs Biotechnology peers
Current Ratio (MRQ)
14.16xvs Biotechnology peers
Book Value per Share (MRQ)
7.59USDUpdated Sep 26, 2026Total Assets
333.17MUSDvs all stocks (USD)
Total Current Assets
332.90MUSDFY2025 · Dec 31, 2025Total Liabilities
25.95MUSDFY2025 · Dec 31, 2025Total Non-current Assets
272.00KUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
0.00USDFY2025 · Dec 31, 2025Total Current Liabilities
25.95MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
45.54MUSDFY2025 · Dec 31, 2025Other Short-term Investments
267.28MUSDFY2025 · Dec 31, 2025Accounts Payable
5.93MUSDFY2025 · Dec 31, 2025Short-term Debt
14.00KUSDFY2025 · Dec 31, 2025Long-term Debt
0.00USDFY2025 · Dec 31, 2025Common Stock (Book)
4.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-404.64MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
307.22MUSDvs all stocks (USD)
52-Week Low
17.00USDUpdated Sep 26, 202652-Week High
35.83USDUpdated Sep 26, 202652-Week Change
56.66%vs all stocks
Beta
1.36xvs all stocks
50-Day MA
30.11USDUpdated Sep 26, 2026200-Day MA
27.18USDUpdated Sep 26, 2026Avg 10-Day Volume
674.42KSharesUpdated Sep 26, 2026Avg 30-Day Volume
535.04KSharesUpdated Sep 26, 2026Diluted EPS (TTM)
-3.55USDUpdated Sep 26, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.12×)Notable
Debt-to-equity: 0.00Industry median: 0.12Industry P5: 0.00Peers compared: 193
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.68
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 33,357,653.812
Market cap is $1.4B, above the global median of $1.18BNotable
Market cap (USD): 1,402,804,890Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
Pacific Shuanglin Bio-Pharmacy Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Phibro Animal Health Corporation
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Jolly Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
SUDEEPPHRM
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shandong Xinhua Pharmaceutical Company Limited
Tier 1ProductionApproval-Gated PipelineRuleFlow
Chongqing Genrix Biopharma Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Ultragenyx Pharmaceutical Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Tianjin Chase Sun Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
KalVista Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
HBM Holdings Limited
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking